Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2018-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14712598.2018.1439014PMID 29431519
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity

  2017cited by this paper
• Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects

  2017cited by this paper
• Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

  2017cited by this paper
• Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment

  2017cited by this paper
• Gut feelings about diabetes and GLP‐1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders

  2017cited by this paper
• P5349Absence of QTc prolongation with semaglutide: a thorough QT/QTc study in healthy subjects

  2017cited by this paper
• Standards of Medical Care in Diabetes—2017 Abridged for Primary Care Providers

  2017cited by this paper
• Absorption, metabolism and excretion of the GLP‐1 analogue semaglutide in humans and nonclinical species

  2017cited by this paper
• Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

  2017cited by this paper
• Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

  2017cited by this paper
• Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.

  2017cited by this paper
• Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

  2017cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4)

  2016cited by this paper
• Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)

  2016cited by this paper
• Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3)

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel

  2015cited by this paper
• The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

  2015cited by this paper
• How individuals with the irritable bowel syndrome describe their own symptoms before formal diagnosis

  2015cited by this paper
• A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

  2015cited by this paper
• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates

  2014cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2014cited by this paper
• Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.

  2014cited by this paper
• Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials

  2013cited by this paper
• Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

  2013cited by this paper
• Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.

  2010cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008influential reference
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

  1996cited by this paper

• GLP-1R Agonists and Muscle Health: Potential Role in Sarcopenia Prevention and Treatment.

  2025cites this paper
• Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists

  2025cites this paper
• Perioperative GLP-1 Receptor Agonist Use Is Not Associated with Increased Complications in Obese Patients Undergoing Total Shoulder Arthroplasty: A Propensity-Matched Large Database Study

  2025cites this paper
• How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis

  2025cites this paper
• The impact of semaglutide and tirzepatide on skeletal muscle: Significant benefit or substantial risk?

  2025cites this paper
• Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy

  2024cites this paper
• DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model

  2022influential citation
• The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review

  2022cites this paper
• Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress

  2022cites this paper
• Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases

  2022cites this paper
• A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease

  2022cites this paper
• Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6

  2022cites this paper
• Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6

  2022cites this paper
• Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis.

  2020cites this paper
• The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke.

  2019cites this paper
• Rational combination therapy for type 2 diabetes.

  2019cites this paper
• Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease

  2019cites this paper
• Semaglutide as a promising antiobesity drug

  2019cites this paper
• Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.

  2018cites this paper